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A B S T R A C T
Visceral leishmaniasis is an infection with an insidious and disabling course caused by parasites of the
genus Leishmania. In Europe, it is mostly associated with HIV infection. Systemic lupus erythematosus
and its treatment are associated with increased risk of infection, neoplastic and concomitant
autoimmune disorders. The association of these diseases may go unnoticed.
A 60 year-old Caucasian woman with lupus presented with a one-year history of fever, malaise,
weakness and weight loss. The highlights on physical examination were pallor, palpable hepatosple-
nomegaly and low-grade fever. Blood tests showed pancytopenia, hyperproteinemia with hypoalbu-
minemia and hypergammaglobulinemia; electrophoresis showed a polyclonal gamma curve. Full-body
CT scan revealed massive hepatosplenomegaly. Microbiology investigation was negative for the most
common pathogens, including tuberculosis. There were no signs of hematologic malignancy in the bone
marrow smear. PCR for Leishmania infantum was positive both in blood and bone marrow. The patient
was treated with liposomal amphotericin B, and immunosuppression was adjusted. She showed rapid
clinical improvement and 6 months later had no signs of disease.
The differential diagnosis in a patient with lupus presenting with fever and multisystemic
manifestations includes infectious or neoplastic disorders. The patient lived in an endemic area of
Leishmania, and typical clinical and analytical changes were all present, making this case highly
educational. The case highlights the importance of a patient’s epidemiological background and how it
can lead to the diagnosis and timely treatment of a rare disease.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Visceral leishmaniasis (VL) is a systemic infection with a
worldwide distribution caused by protozoan parasites of the genus
Leishmania. Leishmania spp. are transmitted to human and animal
hosts through the bite of female sandﬂies from the generaAbbreviations: AmB, amphotericin B; ANA, anti-nuclear antibodies; CMV, cyto-
megalovirus; CT, computerized tomography; dsDNA, double-stranded deoxyribo-
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primary care physician; PCR, polymerase chain reaction; RNA, ribonucleic acid; SLE,
systemic lupus erythematosus; VL, visceral leishmaniasis; WBC, white blood cell
count.
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4.0/).Phlebotomus, in the Old World, and Lutzomiya, in the New World
[1]. Dogs and other canines, independent of the clinical form of VL,
are the main reservoirs of Leishmania and represent the major
source of contagion for the vector [2].
Human infection occurs when female sandﬂies hosting the
parasite feed on the human host, in order to ingest blood, and
directly inoculate the parasite into the bloodstream. The promas-
tigotes, motile forms transmitted by the sandﬂy, are phagocytized,
ﬁrst by neutrophils and then by macrophages, transform into
amastigotes, the nonmotile form – and the one usually present at
diagnosis – and multiply within the macrophages, eventually
disseminating and infecting the whole reticuloendothelial system
[2]. Parasites and infected macrophages can metastasize within the
skin and mucosa, bone marrow, lymph nodes, liver and spleen,
resulting in skin and mucosal lesions of cutaneous leishmaniasis,
progressive enlargement of internal organs and lymph nodes, and
suppression of bone marrow. Host control of infection is a complexe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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incompletely understood [3]. The disease has, therefore, a wide
spectrum of clinical manifestations and severity, from asymptom-
atic infection to acute or chronic and insidious life-threatening
condition. The hallmarks are fever, pancytopenia, hepatospleno-
megaly, and low albumin with and increased protein count due to
hypergammaglobulinemia [2].
Depending on whether or not a reservoir host is present, there
are two basic types of epidemiological cycles: zoonotic, generally
caused by Leishmania infantum, which occurs in the Mediterranean
Basin, China, the Middle East, and South America, and anthro-
ponotic, generally caused by L. donovani, which is prevalent in East
Africa, Bangladesh, India, and Nepal [4]. The latest estimates point
to an annual incidence of 200,000–300,000 cases of VL across 98
countries, with more than 90% occurring in the Indian subconti-
nent, East Africa and Brazil [5]. The overall case-fatality rate is
estimated at 10% [5], but can be up to 20–50% in immunocompro-
mised hosts [6,7]. In Europe the species responsible for auto-
chthone VL is L. infantum, with an estimated annual incidence of
around 1200–2000 cases, and it is endemic in countries in the
Mediterranean basin, especially Italy and Turkey, but also in
Portugal [5,8]. In these countries, it is diagnosed almost exclusively
in malnourished children and in adults infected with the human
immunodeﬁciency virus (HIV).
Systemic lupus erythematosus (SLE) is an autoimmune disease
of unknown etiology classically characterized by chronic multi-
systemic inﬂammation. It is characterized by polyclonal activation
of B lymphocytes with production of multiple autoantibodies.
Many patients alternate between periods of exacerbation (ﬂares)
and reduced disease activity. Patients with SLE, due to the disease
but also due to treatment with immunosuppressive drugs, are at
increased risk for infections that can greatly complicate its course
[9]. Some infections, such as VL, can even mimic a ﬂare. Because
lupic ﬂares are common, clinical suspicion of VL is usually very low,
and the diagnosis may go unnoticed.
Case
A retired 60 year-old Caucasian female with SLE was admitted
to the Rheumatology Department in our hospital with persistent
low-grade fever, night sweats, malaise, weakness and weight loss.
She had no neurologic, respiratory, gastrointestinal or urinary
symptoms, and no cutaneous lesions or joint pain, although she
had a sensation of abdominal fullness. The symptoms had started
approximately one year earlier, had shown progressive worsening,
and she had lost 30 kg (approximately 1/3 of her previous body
weight). During that time she was seen by her primary care
physician (PCP) on several occasions and had several consultations
with her rheumatologist. The investigation performed had been
negative for common pathogens associated with chronic febrile
illnesses, such as tuberculosis and brucellosis, and progression of
immunosuppression had not stalled the symptoms. The patient
had been treated for presumptive tuberculosis for 6 months,
having shown no signs of improvement.
The patient had been diagnosed with SLE in her late 20s, had
consultations with a rheumatologist in our hospital since 2003,
and was being treated with a daily dose of 5 mg prednisolone and a
weekly 10 mg dose of methotrexate. She also had diabetes mellitus
and hypertension, both being treated by her PCP. Her SLE had been
deemed controlled until these symptoms started, and she had no
past history of conﬁrmed tuberculosis or any chronic febrile
infection. An HIV screening performed by her PCP had been
negative. She had no past surgeries and no family history of cancer.
The patient lived in a farm, in a town located in the region of the
Douro river basin, in the north of the country. She had no history of
smoking or of any drug use.On admission, the only abnormalities were a low-grade fever
(37.5 8C), marked pallor and a palpable, non-tender hepatosple-
nomegaly. Her blood pressure was 105/63 mmHg, heart and
respiratory rates were 84/min and 18/min, respectively. There
were no abnormalities on cardiac or lung auscultation, no rash, and
her neurologic examination was unremarkable. A careful exami-
nation revealed no swelling, redness or pain of any joint.
Preliminary analytical study revealed pancytopenia, with a
hemoglobin of 8.0 g/dL, white blood cell count (WBC) of 3020/
mm3, and platelet count of 98,000/mm3, erythrocyte sedimenta-
tion rate (ESR) of 116 mm/h, lactic dehydrogenase (LDH) of
2331 U/L, low serum albumin (18 g/L) with increased total
proteins (90 g/L). Hepatic aminotransferases were slightly elevat-
ed, bilirubin, blood urea nitrogen and creatinine were normal.
Blood was also collected for culture of bacteria, mycobacteria and
fungi, and for serologic study. Chest X-ray showed no opacities,
nodules or effusions; abdominal ultrasound revealed massive
hepatosplenomegaly, with a liver and spleen of 35 cm and 16 cm,
respectively. The ﬁrst diagnostic hypothesis was a hematologic
malignancy, although subacute infections such as brucellosis or
tuberculosis were also considered. A differential protein analysis
with electrophoresis, antibody search, and full body computerized
tomography (CT) scan were performed. A Hematology consultation
was requested.
The patient had marked hypergammaglobulinemia, with a total
gamma globulin count of 7580 mg/L, and a polyclonal gamma
curve was seen on electrophoresis; gamma globulin differential
was normal. There was no complement consumption, anti-nuclear
antibodies (ANA), anti-extractable nuclear antigens (ENA), and
anti-double stranded DNA (anti-dsDNA) antibodies were negative.
Full-body CT conﬁrmed the hepatomegaly and homogeneous
splenomegaly, but did not show any other relevant abnormalities.
Serial blood cultures for bacteria, mycobacteria and fungi were
persistently negative. The serologic study revealed multiple
positive IgG and IgM for Coxiella burnetti, Mycoplasma pneumoniae
and for Rickettsia conorii. IgM for Epstein–Barr virus (EBV),
cytomegalovirus (CMV) and parvovirus B-19 were negative. Blood
and bone marrow cultures for bacteria and fungi were negative.
Bone marrow aspirate and biopsy were performed and sent for
histologic and microbiologic study (culture for bacteria and
mycobacteria). The patient and the preliminary results of the
marrow smear were seen by an experienced hematologist who
considered the patient had no consistent signs of hematologic
malignancy. Amoxicillin/clavulanate and ciproﬂoxacin were em-
pirically administered, but showed to be ineffective.
On day 18 of admission, an infectious diseases (ID) consultation
was requested. The clinical history and the physical examination
were those previously described, but the patient revealed for the
ﬁrst time that she lived next to livestock and that her husband was
a sports hunter, had a pack of dogs, and one had died recently of an
undiagnosed consumptive disease. The hypothesis of visceral
leishmaniasis was considered: the patient had an appropriate
background, prolonged fever and constitutional symptoms,
pancytopenia, and increased protein count with low albumin
and hypergammaglobulinemia. The multiple positive antibodies
were interpreted as resulting from increased gamma globulin
production. Polymerase chain reaction (PCR) for L. infantum was
positive both in the blood and in the bone marrow.
The patient was transferred to the ID Department and was
treated with liposomal amphotericin B (AmB), in a dosing of 3 mg/
kg. She received one daily dose during the ﬁrst 5 days, another one on
day 10, and then once weekly until she completed 10 doses. A
prolonged regimen was chosen due to her long standing immuno-
suppression, long duration of disease, and overall poor clinical
condition. She was discharged on day 29 of admission (10 days after
being transferred to the ID department), after completing her sixth
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body temperature once she started treatment, and recovered some of
the analytical anomalies. The patient completed therapy in our
department’s ambulatory clinic. A histologic review of the bone
marrow biopsy showed histiocytes infected with amastigotes,
conﬁrming our diagnosis, without any signs of primary hematologic
disease.
Six months later, on her second appointment after discharge,
the patient was completely asymptomatic, had recovered 10 kg,
and had an overall normal physical examination. Hemoglobin rose
to 11.7 g/dL, WBC to 7340/mm3, platelet count to 164,000/mm3,
total serum protein was 81 g/L, serum albumin rose to 34 g/L and
globulin count decreased to 5460 mg/L; abdominal ultrasound no
longer showed signs of organ enlargement.
Discussion
The case presented here is the ﬁrst ever reported case of VL in a
lupus patient in Portugal and, based on a very recent review and
case series by Santana et al. [6] and on our own investigation, the
14th described so far in medical literature.
Early recognition of infection in SLE is important as misdiagno-
sis and inadequate treatment (such as augmenting immunosup-
pression) may lead to disastrous consequences. With VL that can
be very difﬁcult, because it is very rare and clinical and laboratory
features may mimic a lupic ﬂare. Some important differences
which may help distinguish between a lupic ﬂare and VL can be
highlighted: almost all patients with VL have splenomegaly, with
or without hepatic enlargement, while those are rare ﬁndings in
SLE ﬂares; on the other hand, aggravated arthralgia or arthritis is
very common in ﬂares, but not common symptoms of VL. In lupus
ﬂares the serum complement levels C3 and C4 are usually
decreased and anti-dsDNA antibodies increased [6,10].
Clinical suspicion, however, comes with the knowledge of a
disease’s epidemiology and clinical presentation. While there are
some endemic foci of leishmaniasis in Portugal, overall incidence is
at 15 cases per year [5]. But even within the country, most areas
have never had a reported case of VL, while others – such as the one
where our patient hailed from – have an incidence rate of 8/
100,000 inhabitants a year [8]. As for the classic manifestations of
VL, our patient manifested all of the typical hallmarks – fever,
malaise, weight loss, pancytopenia, hepatosplenomegaly, and
hyperproteinemia with hypoalbuminemia and hypergammaglo-
bulinemia – which, without making it a unique case, make it
perhaps the most illustrative, paradigmatic and educational of the
few ever reported in SLE patients. A Chinese woman described in
1983 by Wallis and Clark [11], the ﬁrst ever reported similar case,
had all the same features as our patient, but the epidemiological
link to a speciﬁc canine reservoir was more evident in our patient.
The other 12 cases have different combinations of typical ﬁndings,
but not all of them [6,12–15].
Conﬁrmative diagnosis is usually made by observing histiocytes
infected with amastigotes in microscopy of bone marrow smears
or biopsy, hepatic biopsy or splenic aspirate – classically named
Leishman-Donovan bodies [16]. Histology microscopy is more
sensitive than smear observation, but due to its technical
characteristics, it may delay the diagnosis. There are other
laboratory tests that may lead to a quicker conﬁrmation of
diagnosis: culture using triple-N media, detection of antibodies
using recombinant k-39 antigen, and detection of DNA through
PCR [17,18]. The serologic tests have the further advantage of being
used for monitoring [18], but they have mostly been tested with L.
donovani and L. chagasi, not with L. infantum, the existing species in
southern Europe [5]. Both the serologic assay and culture media
are unavailable at our hospital and preliminary observation of
marrow smear had been negative. The patient was very ill and atimely diagnosis was essential. PCR targets the DNA of the
kinetoplast or ribosomal RNA genes, it can be performed in
peripheral blood or in the bone marrow tissue, and studies show it
can have an increased sensitivity for microbiologic diagnosis [17]
as well as faster results, since it only takes a few hours to perform.
There are a number of therapies for VL and current World
Health Organization treatment advice varies by global region [19].
This is partially explained by parasite susceptibility. In many
developing countries, however, where most of the cases are
reported, the cost of treatment is the greatest challenge.
Pentavalent antimony was considered the mainstay of therapy
in VL for decades. However, the precise mechanism of action of this
agent is unknown; it has multiple toxicities and is increasingly
failing due to development of parasite resistance. Furthermore, the
emergence of drug-resistant strains is rapidly increasing world-
wide and these treatments fail to induce a sterile cure because they
do not eliminate persistent parasites from the host [2,16]. A critical
challenge is related to widespread resistance to pentavalent
antimony, especially some areas in India, where it can go up to 60%.
In Europe, liposomal formulations of AmB (LAB) are recom-
mended as ﬁrst-line treatment. Compared to deoxycholate
formulations (‘‘classical’’ AmB), LAB has a more favorable safety
proﬁle and seems to increase anti-leishmanial activity, improving
effectiveness [20]. It is used against several severe fungal infections
which have become much more common in our daily practice,
giving us extensive knowledge of its side effects. There was no
adverse events with treatment in our patient and, as described in
literature [16], the patient became afebrile and asymptomatic
within the ﬁrst week. SLE patients are immunosuppressed both by
the underlying disease and immunosuppressive drugs. Our patient
was on daily prednisolone and, until she was admitted, had been
on methotrexate for several years. The disease was thought to have
at least one year of duration, based on the beginning of symptoms,
and had taken quite a toll on the patient. Because of all those
reasons, we chose the recommended regimen with LAB for
immunocompromised patients [19].
The differential diagnosis in a patient with systemic lupus
erythematosus presenting fever and multisystemic manifestations
is often difﬁcult but must always include infectious or neoplastic
disorders. The patient lived in an endemic focus of Leishmania, and
typical clinical and analytical changes were all present, making this
case highly educational. It also highlights the importance of a
patient’s epidemiological background and how it can lead to the
diagnosis and timely treatment of a rare and deadly disease. The
authors hope it will be able to help guide clinicians who may face a
similar situation.
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